Business
AlzeCure Publishes its Year-End Report for January - December 2025
STOCKHOLM, SE / ACCESS Newswire / February 26, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6) today announced that its Year-end report for the period January - December 2025 is now available on the company's website: www.alzecurepharma.com/en/section/investors/financial-reports/ ...
About this update from Alzecure Pharma Ab
[{"type":"text","content":"STOCKHOLM, SE / ACCESS Newswire / February 26, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6) today announced that its Year-end report for the period January - December 2025 is now available on the company's website: www.alzecurepharma.com/en/section/investors/financial-reports/","length":291,"tagName":"p"},{"type":"text","content":""We had a positive and active fourth quarter of 2025. During the quarter, our focus was on preparing the Phase II study in Alzheimer's patients with NeuroRestore ACD856, for which we were awarded a grant of EUR 2.5 million from the European Innovation Council (EIC). The first disbursement of the grant was made in early December. During the quarter, we also worked on preparations for a potential registrational study for the pain project Painless ACD440, for which we received Orphan Drug Designation (ODD) from the European Medicines Agency (EMA) in February 2026. We have continued to actively participate in business development congresses and to publish new data for several of our projects at world-leading scientific conferences."","length":752,"tagName":"p"},{"type":"text","content":"Martin Jönsson, CEO","length":19,"tagName":"p"},{"type":"text","content":"Financial information for October - December, 2025, GroupFigures in parentheses refer to the corresponding period of the previous year.","length":136,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Net sales during the period totaled SEK 0 thousand (0).","length":55,"tagName":"p"}]},{"val":[{"type":"text","content":"Earnings for the period totaled SEK -17,742 thousand (-9,354).","length":62,"tagName":"p"}]},{"val":[{"type":"text","content":"Earnings per share, basic, totaled SEK -0.15 (-0.11).","length":53,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash flow from operating activities totaled SEK -8,579 thousand (SEK -7,305).","length":77,"tagName":"p"}]},{"val":[{"type":"text","content":"Total assets at the end of the period amounted to SEK 59,043 thousand (39,253).","length":79,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash and cash equivalents at the end of the period totaled SEK 50,336 thousand (31,498).","length":88,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":414,"olType":false},{"type":"text","content":"Financial information for January - December, 2025, Group...